Rigrodsky & Long, P.A. Announces Investigation Of BioClinica, Inc. Buyout
Rigrodsky & Long, P.A.:
-
Do you own shares of BioClinica, Inc. (NASDAQ GM: BIOC)?
-
Did you purchase any of your shares prior to January 30, 2013?
-
Do you think the proposed buyout price is too low?
-
Do you want to discuss your rights?
Rigrodsky
& Long, P.A. announces that it is investigating potential legal
claims against the board of directors of BioClinica, Inc. (“BioClinica”
or the “Company”) (NASDAQ GM: BIOC)
regarding possible breaches of fiduciary duties and other violations of
law related to the Company’s entry into an agreement to be acquired by
JLL Partners, Inc. (“JLL”) in a transaction valued at approximately $123
million.
Click here to learn more: http://www.rigrodskylong.com/investigations/bioclinica-inc-bioc.
Under the terms of the proposal, public shareholders of BioClinica will
receive $7.25 per share in cash for each share of BioClinica they own.
The investigation concerns whether BioClinica’s board of directors
failed to adequately shop the Company and obtain the best possible value
for BioClinica’s shareholders before entering into an agreement with
JLL. According to Yahoo! Finance, at least one analyst has set a price
target for BioClinica stock at $9.00.
If you own the common stock of BioClinica and purchased your shares
before January 30, 2013, if you have information or would like to learn
more about these claims, or if you wish to discuss these matters or have
any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Peter Allocco at Rigrodsky
& Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York
11530 toll free at (888) 969-4242, by e-mail to info@rigrodskylong.com,
or at: http://www.rigrodskylong.com/investigations/bioclinica-inc-bioc.
Rigrodsky
& Long, P.A., with offices in Wilmington, Delaware and Garden
City, New York, regularly prosecutes securities
class, derivative and direct actions, shareholder rights litigation and
corporate governance litigation, on behalf of shareholders in states
and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
